Correlation Between Enorama Pharma and Enzymatica Publ

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Enorama Pharma and Enzymatica Publ at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enorama Pharma and Enzymatica Publ into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enorama Pharma AB and Enzymatica publ AB, you can compare the effects of market volatilities on Enorama Pharma and Enzymatica Publ and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enorama Pharma with a short position of Enzymatica Publ. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enorama Pharma and Enzymatica Publ.

Diversification Opportunities for Enorama Pharma and Enzymatica Publ

0.8
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Enorama and Enzymatica is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Enorama Pharma AB and Enzymatica publ AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enzymatica publ AB and Enorama Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enorama Pharma AB are associated (or correlated) with Enzymatica Publ. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enzymatica publ AB has no effect on the direction of Enorama Pharma i.e., Enorama Pharma and Enzymatica Publ go up and down completely randomly.

Pair Corralation between Enorama Pharma and Enzymatica Publ

Assuming the 90 days trading horizon Enorama Pharma AB is expected to generate 1.46 times more return on investment than Enzymatica Publ. However, Enorama Pharma is 1.46 times more volatile than Enzymatica publ AB. It trades about 0.07 of its potential returns per unit of risk. Enzymatica publ AB is currently generating about -0.06 per unit of risk. If you would invest  235.00  in Enorama Pharma AB on September 1, 2024 and sell it today you would earn a total of  111.00  from holding Enorama Pharma AB or generate 47.23% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Enorama Pharma AB  vs.  Enzymatica publ AB

 Performance 
       Timeline  
Enorama Pharma AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Enorama Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Enzymatica publ AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Enzymatica publ AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Enzymatica Publ is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Enorama Pharma and Enzymatica Publ Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Enorama Pharma and Enzymatica Publ

The main advantage of trading using opposite Enorama Pharma and Enzymatica Publ positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enorama Pharma position performs unexpectedly, Enzymatica Publ can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enzymatica Publ will offset losses from the drop in Enzymatica Publ's long position.
The idea behind Enorama Pharma AB and Enzymatica publ AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Complementary Tools

Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets